



ASX / MEDIA RELEASE

29 December 2008

CELLSENSE MERGES WITH BIOCELL

The Board of Stirling Resources Limited (ASX:SRE), formally known as Alexanders Securities Limited (ASX:ALE), is pleased to announce that its Private Cord Blood HealthCare Subsidiary, Cellsense Pty Ltd ("Cellsense"), has reached an agreement to merge with Biocell Pty Ltd ("Biocell") to operate under the new name "Australian Stem Cell HealthCare Pty Ltd" to form the largest Private Cord Blood Stem Cell Bank in Australia. The merger will be achieved through the issue of Biocell shares to effect a 50:50 merger with Cellsense. The transaction will be cash positive from day 1, excluding the one-off abnormal costs of merging the 2 companies.

The Cellsense merger with Biocell represents a significant milestone in the expansion of Australian private cord blood collection and storage services, which will bring sustainability, stability and clarity to this emerging industry that represents the future of health care.

The impacts of the use of cord blood stem cells in the treatment of a wide variety of conditions is increasing at a rapid rate as medical research and clinical application unlock the potential that stem cells can provide, which is reflected in the uptake rates around the world ranging from 4% to 7% in the USA and Europe and up to 23% in Singapore and 45% in Korea.

This merger will bring together the best of both companies. Cellsense and Biocell will become differentiated product brands within Australian Stem Cell HealthCare Pty Ltd, which will result in high quality and affordable products as well as affordable and secure services Australia wide.

Announcing the merger, Cellsense's CEO, Dr Anthony Coulepis, said "We are delighted to have reached agreement with Biocell and its majority shareholder, Cordlife Limited, which has extensive experience in private cord blood banking around the world. We look forward to this merger, which will deliver world's best practice to Australian families providing them with a dynamic, customer-focused and high quality service offering". Dr Coulepis added that Cellsense's merger with Biocell would create a strong platform for future expansion in Australia.

"I am also looking forward to working with my counterpart and Biocell Founder, Professor Mark Kirkland, who is an eminent physician and researcher in the stem cell space, as we jointly bring together the 2 companies with a consolidated strong Management Team, to establish Australian Stem Cell HealthCare Pty Ltd as the premier private cord blood banking company in Australia, with a focus on quality, service excellence and professional standards", Dr Coulepis said.

Dr Coulepis added that he believed the "cultural fit" and vision between Cellsense and Biocell was excellent and therefore this merger would deliver synergies that would benefit the industry, its doctors, healthcare professional and most importantly the parents and their families.

Mr Paul Page, a spokesperson for Stirling Resources Limited, said, "We are very pleased with this merger outcome as a way forward for our Stem Cell HealthCare business and, as a 50% and the largest shareholder of the merged entity, we wish Australian Stem Cell HealthCare all the very best in the important role in delivering therapeutic outcomes for families.

For further information please contact:

Dr Anthony (Tony) Coulepis
Chief Executive Officer
Stirling Resources Limited
Tel: 0419 436 902